Circulating microRNAs as potential biomarkers for monitoring the response to in vivo treatment with Rituximab in systemic lupus erythematosus patients
- 1 April 2020
- journal article
- letter
- Published by Elsevier in Autoimmunity Reviews
- Vol. 19 (4) , 102488
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Post-Translational Modification Control of Innate ImmunityImmunity, 2016
- Longer duration of B cell depletion is associated with better outcomeRheumatology, 2015
- Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritisNephrology Dialysis Transplantation, 2012
- MicroRNA in autoimmunity and autoimmune diseasesJournal of Autoimmunity, 2009
- Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosusAnnals of the Rheumatic Diseases, 2008
- Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1997